Advanced search
Publication Cover
Clinical Ophthalmology Volume 18, 2024 - Issue
Submit an article Journal homepage
146
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review

Constance O Okeke1 Virginia Eye Consultants/CVP, Norfolk, VA, USACorrespondence[email protected]
View further author information
,
Nora Lee Cothran2 The Eye Institute of West Florida, Largo, FL, USAORCID Iconhttps://orcid.org/0009-0007-1645-1796View further author information
ORCID Icon,
Desirae A Brinkley3 Eye Specialty Group, Memphis, TN, USAView further author information
,
Kamran Rahmatnejad4 Eastern Virginia Medical School, Norfolk, VA, USAView further author information
,
Frank J Rodiño5 Churchill Outcomes Research, Red Bank, NJ, USAView further author information
&
James E Deom6 Hazleton Eye Specialists, Hazle Township, PA, USAView further author information
Pages 409-422 | Received 19 Oct 2023, Accepted 15 Jan 2024, Published online: 06 Feb 2024

References

  • Centers for Disease Control and Prevention. Vision health initiative: don’t let glaucoma steal your sight; 2020. Available from: https://www.cdc.gov/visionhealth/resources/features/glaucoma-awareness.html#:~:text=About%203%20million%20Americans%20have,know%20they%20have%20the%20disease. Accessed November 15, 2022.
  • Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. doi:10.1136/bjo.2005.081224
  • Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234. doi:10.1016/S2214-109X(17)30393-5
  • Gupta P, Zhao D, Guallar E, Ko F, Boland MV, Friedman DS. Prevalence of glaucoma in the United States: the 2005–2008 national health and nutrition examination survey. Invest Ophthalmol Vis Sci. 2016;57(6):2905–2913. doi:10.1167/iovs.15-18469
  • Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:10.1001/archopht.120.6.701
  • Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC. Vyzulta (Latanoprostene Bunod Ophthalmic Solution). Bridgewater, NJ: Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC; 2018.
  • Cavet ME, DeCory HH. The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1–2):52–60. doi:10.1089/jop.2016.0188
  • Kawase K, Vittitow JL, Weinreb RN, Araie M, Study Group JUPITER. Long-term safety and efficacy of Latanoprostene Bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the Jupiter study. Adv Ther. 2016;33(9):1612–1627. doi:10.1007/s12325-016-0385-7
  • Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965–973. doi:10.1016/j.ophtha.2016.01.019
  • Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27(1):7–15. doi:10.1097/IJG.0000000000000831
  • Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of Latanoprostene Bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250–259. doi:10.1016/j.ajo.2016.05.012
  • Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL. VOYAGER study group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open-angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–745. doi:10.1136/bjophthalmol-2014-305908
  • Radell JE, Sharma HK, Auyeung KL, et al. Two-year experience with Latanoprostene Bunod in clinical practice. J Glaucoma. 2021;30(9):776–780. doi:10.1097/IJG.0000000000001904
  • Zhou B, Bekerman VP, Khouri AS. Use of Latanoprostene Bunod as adjunctive glaucoma therapy in refractory glaucoma. J Curr Glaucoma Pract. 2022;16(3):166–169. doi:10.5005/jp-journals-10078-1386
  • Mehta AA, Kanu LN, Sood-Mendiratta S, et al. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma. Eur J Ophthalmol. 2022;32(1):322–326. doi:10.1177/1120672121998913
  • Wang Y, Liao Y, Nie X. Comparative evaluation of latanoprostene bunod, timolol maleate, and latanoprost ophthalmic solutions to assess their safety and efficacy in lowering intraocular pressure for the management of open-angle Glaucoma. Clinics. 2020;75:e1874.
  • Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52(5):2147–2152. doi:10.1167/iovs.10-6342
  • Liu B, McNally S, Kilpatrick JI, Jarvis SP, O’Brien CJ. Aging and ocular tissue stiffness in glaucoma. Surv Ophthalmol. 2018;63(1):56–74. doi:10.1016/j.survophthal.2017.06.007
  • Okeke CO, Burstein ES, Trubnik V, et al. Retrospective chart review on real-world use of Latanoprostene Bunod 0.024% in treatment-naïve patients with open-angle glaucoma. Ophthalmol Ther. 2020;9(4):1041–1053. doi:10.1007/s40123-020-00307-0
  • Francis BA, Varma R, Chopra V, Lai MY, Shtir C, Azen SP; Los Angeles Latino Eye Study Group. Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008;146(5):741–746. doi:10.1016/j.ajo.2008.05.048

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.